Department of Physical Pharmaceutics - Faculty of Life Sciences Kumamoto University

  • HomeHome
  • MembersMembers
  • Research ProjectsResearch Projects
  • PublicationsPublications
  • Doctoral DegreeDoctoral Degree
  • EventsEvents
  • Photo AlbumPhoto Album

Publications

  1. Dual targeting system by supramolecular complex of folate-conjugated methyl-b-cyclodextrin with adamantane-grafted hyaluronic acid for the treatment of colorectal cancer.
    K.M. Elamin, K. Motoyama, T. Higashi, Y. Yamashita, A. Tokuda, H. Arima.
    Int. J. Biol. Macromol., 113, 386-394 (2018).
  2. Supramolecular complex of methyl-b-cyclodextrin with adamantane-grafted hyaluronic acid as a novel antitumor agent
    K.M. Elamin, T. Higashi, K. Motoyama, Y. Yamashita, H. Arima
    Chem. Pharm. Bull., 66(3), 277-285 (2018).
  3. Anti-allergic Effects of Novel Sulfated Polysaccharide Sacran on Mouse Model of 2,4-Dinitro-1-fluorobenzene-induced Atopic Dermatitis
    K. Motoyama, Y. Tanida, A. Sakai, T. Higashi, S. Kaneko, H. Arima
    Int. J. Biol. Macromol., 108, 112-118 (2018).
  4. Role of 6-O- a-maltosyl- b-cyclodextrin in lysosomal cholesterol deprivation in Npc1-deficient Chinese hamster ovary cells
    Y. Okada, E. Ueda, Y. Kondo, Y. Ishitsuka, T. Irie, T. Higashi, K. Motoyama, H. Arima, M. Matuso, K. Higaki, K. Ohno, J. Nishikawa, A. Ichikawa
    Carbohydr. Res. , 455, 54-61 (2018).
  5. In vitro and in vivo siRNA delivery to hepatocyte utilizing ternary complexation of lactosylated dendrimer/cyclodextrin conjugates, siRNA and low-molecular-weight sacran
    Y. Hayashi, T. Higashi, K. Motoyama, H. Jono, Y. Ando, H. Arima
    Int. J. Biol. Macromol., 117(Pt A), 1113-1121 (2018).
  6. Involvement of mitophagy-mediated cell death in colon cancer cells by folate-appended methyl-b-cyclodextrin
    K.M. Elamin, Y. Yamashita, K. Motoyama, T. Higashi, H. Arima
    J. Incl. Phenom. Macro. Chem, 89, 333-342 (2017).
  7. Comparison of ovalbumin and ovalbumin epitope peptide for transdermal delivery and vaccination mediated by the photothermal effect of gold nanorods
    A.T. Haine, Y. Miyamoto, T. Higashi, K. Motoyama, H. Arima, T. Niidome
    J. Biomater. Sci. Polym., 28(16), 1888-1898 (2017).
  8. A clue to unprecedented strategy to HIV eradication:"Lock-in and apoptosis"
    H. Tateishi, K. Monde, K. Anraku, R. Koga, Y. Hayashi, H.I. Ciftci, H. DeMirci, T. Higashi, K. Motoyama, H. Arima, M. Otsuka, M. Fujita
    Sci. Rep., 7(1), 8957 (2017).
  9. Sustained Release System of siRNA Complex with Polyethylene glycol-appended a-Cyclodextrin/dendrimer Conjugate from Cyclodextrin Polypseudorotaxanes
    K. Morita, K. Motoyama, T. Higashi, K. Hayashida, I.I. Abu Hashim, H. Arima
    J. Drug Des. Res., 4(6), 1056, 1-7 (2017).
  10. Enhancement of Transdermal Protein Delivery by Photothermal Effect of Gold Nanorods Coated on Polysaccharide-based Hydrogel
    A.T. Haine, Y. Koga, Y. Hashimoto, T. Higashi, K. Motoyama, H. Arima, T. Niidome
    Eur. J. Pharm. Biopharm., 119, 91-95 (2017).
  11. Anti-allergic and Profilaggrin (ProFLG)-mRNA expression modulatory effects of sacran
    N.R. Ngatu, K. Motoyama, Y. Nishimura, M.K. Okajima, R. Hirota, T. Higashi, S. Lee, H. Arima, M. Ikeda, S. Nojima, T. Kaneko
    Int. J. Biol. Macromol., 105(Pt 2), 1532-1538 (2017).
  12. Induction of Mitophagy-mediated Antitumor Activity with Folate-appended Methyl-b-cyclodextrin
    K. Kameyama, K. Motoyama, N. Tanaka, Y. Yamashita, T. Higashi, H. Arima
    Int. J. Nanomedicine, 12, 3433-3446(2017).
  13. Ternary complexes of folate-PEG-appended dendrimer (G4)/a-cyclodextrin conjugate, siRNA and low-molecular-weight polysaccharide sacran as a novel tumor-selective siRNA delivery system
    A. Ohyama, T. Higashi, K. Motoyama, H. Arima
    Int. J. Biol. Macromol., 99, 21-28 (2017).
  14. Enhancement of Curcumin Wound Healing Ability by Complexation with 2-Hydroxypropyl-g-cyclodextrin in Sacran Hydrogel Film
    N. Wathoni, K. Motoyama, T. Higashia, M. Okajima, T. Kaneko, H. Arima
    Int. J. Biol. Macromol., 98, 268-276 (2017).
  15. Cyclodextrin-based sustained and controllable release system of insulin utilizing the combination system of self-assembly PEGylation and polypseudorotaxane formation
    T. Hirotsu, T. Higashi, K. Motoyama, H. Arima
    Carbohydr. Polym., 164, 42-48 (2017).
  16. Self-assembly PEGylation Retaining Activity (SPRA) Technology via a Host-guest Interaction Surpassing Conventional PEGylation Methods of Proteins
    T. Hirotsu, T. Higashi, I.I. Abu Hashim, S. Misumi, K. Wada, K. Motoyama, H. Arima
    Mol. Pharm., 14(2), 368-376 (2017).
  17. Stabilizing Effects for Antibody Formulations and Safety Profiles of Cyclodextrin Polypseudorotaxane Hydrogels
    T. Higashi, N. Ohshita, T. Hirotsu, Y. Yamashita, K. Motoyama, S. Koyama, R. IIbuchi, T. Uchida, S. Mieda, K. Handa, T. Kimoto, H. Arima
    J. Pharm. Sci., 106(5), 1266-1274 (2017).
  18. Fabrication of Multi-lactose-appended b-Cyclodextrin and its Cholesterol Lowering Effects in Niemann-Pick Type C Disease-like HepG2 Cells
    K. Motoyama, R. Nishiyama, Y. Maeda, T. Higashi, Y. Ishitsuka, Y. Kondo, T. Irie, T. Era. H. Arima
    Beilstein J. Org. Chem., 13, 10-18 (2017).
  19. Enhancing Effect of g-Cyclodextrin on Wound Dressing Properties of Sacran Hydrogel Film
    N. Wathoni, K. Motoyama, T. Higashi, M. Okajima, T. Kaneko, H. Arima
    Int. J. Biol. Macromol., 94(Pt A), 181-186 (2017).
  20. Cholesterol-lowering Effect of Octaarginine-appended b-Cyclodextrin in Npc1-trap-CHO Cells.
    K. Motoyama, R. Nishiyama, Y. Maeda. T. Higashi, Y. Kawaguchi, S. Futaki, Y. Ishitsuka, Y. Kondo, T. Irie, T. Era, H. Arima
    Biol. Pharm. Bull., 39(11), 1823-1829 (2016).
  21. Ternary inclusion complex formation and stabilization of limaprost, a prostaglandin E1 derivative, in the presence of a- and b-cyclodextrins in the solid state.
    Y. Inoue, D. Iohara, N. Sekiya, M. Yamamoto, H. Ishida, Y. Sakiyama, F. Hirayama, H. Arima, K. Uekama.
    Int. J. Pharm., 509(1-2), 338-347 (2016).
  22. Physically Crosslinked-Sacran Hydrogel Films for Wound Dressing Application
    N. Wathoni, K. Motoyama, T. Higashi, M. Okajima, T. Kaneko, H. Arima
    Int. J. Biol. Macromol., 89, 465-470 (2016).
  23. In vitro evaluation of 2-hydroxyalkylated b-cyclodextrins as potential therapeutic agents for Niemann-Pick Type C disease
    Y. Kondo, H. Tokumaru, Y. Ishitsuka, T. Matsumoto, M. Taguchi, K. Motoyama, T. Higashi, H. Arima, M. Matsuo, K. Higaki, K. Ohno, T. Irie
    Mol. Genet. Metab., 118(3), 214-219 (2016).
  24. Effects of dendrimer/cyclodextrin conjugates as gene transfer carriers on nitric oxide production from macrophages. K. Motoyama, A. Sako, I.I. Abu Hashim, T. Higashi, H. Arima
    J. Pharm. Pharmacol., 68(5), 598-607 (2016).
  25. Anti-inflammatory Effects of Novel Polysaccharide Sacran Extracted from Cyanobacterium Aphanothece sacrum in Various Inflammatory Animal Models
    K. Motoyama, Y. Tanida, K. Hata, T. Hayashi, I.I. Abu Hashim, T. Higashi, Y. Ishitsuka, Y. Kondo, T. Irie, S. Kaneko, H. Arima
    Biol. Pharm. Bull., 39(7), 1172-1178 (2016).
  26. Clinical Evaluation of Novel Natural Polysaccharides Sacran as a Skincare Material for Atopic Dermatitis Patients
    S. Fukushima, K. Motoyama, Y. Tanida, T. Higashi, Y. Ishitsuka, Y. Kondo, T. Irie, T. Tanaka, H. Ihn, H. Arima
    J. Cosm. Derm. Sci. Appl., , 6(1), 1-10 (2016).
  27. In Vitro and In Vivo Tumor-targeting siRNA Delivery Using Folate-PEG-appended Dendrimer (G4)/a-Cyclodextrin Conjugates
    A. Ohyama, T. Higashi, K. Motoyama, H. Arima
    Bioconjug. Chem., 27(3), 521-532 (2016).
  28. Thermoresponsive Formation of Dimethyl Cyclodextrin Polypseudorotaxanes and Subsequent One-pot Synthesis of Polyrotaxanes
    T. Higashi, L. Jun, X. Song, J. Zhu, M. Taniyoshi, F. Hirayama, D. Iohara, K. Motoyama, H. Arima
    ACS Macro Lett., 5(2), 158-162 (2016).
  29. Improvement of Pharmaceutical Properties of Isoprenoid Compounds through the Formation of Cyclodextrin Pseudorotaxane-like Supramolecules
    T. Higashi, H. Tanaka, A. Yoshimatsu, H. Ikeda, K. Arima, M. Honjo, C. Iwamoto, K. Motoyama, H. Arima
    Chem. Pharm. Bull., 64(4), 340-345 (2016).
  30. 2-Hydroxypropyl-b-cyclodextrin acts as a novel anticancer agent M. Yokoo, Y. Kubota, K. Motoyama, T. Higashi, M. Taniyoshi, H. Tokumaru, R. Nishiyama, Y. Tabe, S. Mochinaga, A. Sato, N. Sueoka-Aragane, E. Sueoka, H. Arima, T. Irie, S. Kimura
    PLos One, 10(11), e0141946 (2015).
  31. Cholesterol Lowering Effects of Mono-lactose-appended b-Cyclodextrin in Niemann-pick Type C Disease-like HepG2 Cells K. Motoyama, Y. Hirai, R. Nishiyama, Y. Maeda, T. Higashi, Y. Ishitsuka, Y. Kondo, T. Irie, T. Era, H. Arima
    Beilstein J. Org. Chem., 11, 2079-2086 (2015).
  32. Design and Evaluation of the Highly-concentrated Human IgG Formulation Using Cyclodextrin Polypseudorotaxane Hydrogels. T. Higashi, A. Tajima, N. Ohshita, T. Hirotsu, I.I. Abu Hashim, K. Motoyama, S. Koyama, R. Iibuchi, S. Mieda, K. Handa, T. Kimoto, H. Arima.
    AAPS PharmSciTech, 16(6), 1290-1298 (2015).
  33. Potential Use of Thioalkylated Mannose-modified Dendrimer (G3)/a-Cyclodextrin Conjugate as a NF-kB siRNA Carrier for the Treatment of Fulminant Hepatitis K. Motoyama, R. Mitsuyasu, C. Akao, I.I. Abu Hashim, N. Sato, T. Tanaka, T. Higashi, H. Arima
    Mol. Pharm., 12(9), 3129-3136 (2015).
  34. Inhibition of insulin amyloid fibril formation by cyclodextrins. K. Kitagawa, Y. Misumi, M. Ueda, Y. Hayashi, M. Tasaki, K. Obayashi, T. Yamashita, H. Jono, H. Arima, Y. Ando
    Amyloid, 22(3), 181-186 (2015).
  35. Effects of Cyclodextrins on GM1-Gangliosides in Fibroblasts from GM1-Gangliosidosis Patients. Y. Maeda, K. Motoyama, T. Higashi, Y. Horikoshi, T. Takeo, N. Nakagata, Y Kurauchi, H. Katsuki, Y. Ishitsuka, Y. Kondo, T. Irie, H. Furuya, T. Era, H. Arima.
    J. Pharm. Pharmacol., 67(8), 1133-1142 (2015).
  36. Efficacy of 2-hydroxypropyl-b-cyclodextrin in Niemann-Pick disease type C model mice and its pharmacokinetic analysis in a patient with the disease Y. Tanaka, Y. Ishitsuka, Y. Yamada, M. Matsuo, K. Shiraishi, K. Wada, Y. Uchio, Y. Kondo, T. Takeo, N. Nakagata, T. Higashi, K. Motoyama, H. Arima, S. Mochinaga, K. Higaki, K. Ohno, T. Irie.
    Biol. Pharm. Bull., 38(6), 844-851 (2015).
  37. Evaluation of Antitumor Effect of Folate-conjugated Methyl-b-cyclodextrin for Melanoma K. Motoyama, R. Onodera, N. Tanaka, K. Kameyama, T. Higashi, R. Kariya, S. Okada, H. Arima
    Biol. Pharm. Bull., 38(3), 374-379 (2015).
  38. The antitumor effects of methy-b-cyclodextrin against primary effusion lymphoma via the depletion of cholesterol from lipid rafts K. Gotoh, R. Kariya, M. M. Alam, K. Matsuda, S. Hattori, Y. Maeda, K. Motoyama, A. Kojima, H. Arima, S. Okada
    Biochem. Biophys. Res. Commun., 455(3-4), 285-289 (2014).
  39. Preparation and evaluation of cyclodextrin polypseudorotaxane with PEGylated liposome as a sustained release drug carrier K. Hayashida, T. Higashi, D. Kono, K. Motoyama, K. Wada, H. Arima
    Beilstein J. Org. Chem., 10, 2756-2764 (2014).
  40. Potential use of fucose-appended dendrimer/a-cyclodextrin conjugates as NF-kB decoy carriers for the treatment of lipopolysaccharide-induced fulminant hepatitis in mice C. Akao, T. Tanaka, R. Onodera, A. Ohyama, N. Sato, K. Motoyama, T. Higashi, H. Arima
    J. Control. Release, 193(10), 35-41 (2014).
  41. Design and Evaluation of Thioalkylated Mannose-modified Dendrimer (G3)/a-Cyclodextrin Conjugates as Antigen Presenting Cells-selective siRNA Carriers K. Motoyama, R. Mitsuyasu, C. Akao, T. Tanaka, A. Ohyama, N. Sato, T. Higashi, H. Arima
    AAPS J., 16(6), 1298-1308 (2014).
  42. Effects of intrathecal administration of 2-hydroxypropyl-b-cyclodextrin in patients with Niemann-Pick Type C disease M. Matsuo, K. Shraishi, K. Wada, Y. Ishitsuka, H. Doi, M. Iimori, T. Mizoguchi, J. Eto, S. Mochinaga, H. Arima, T. Irie
    Mol. Genet. Metab. Rep., in press (2014).
  43. Preparation and evaluation of polyamidoamine dendrimer conjugate with glucuronylglucosyl-b-cyclodextrin (G3) as a novel carrier for siRNA A.F. Abdelwahab, A. Ohyama, T. Higashi, K. Motoyama, K.A. Khaled, H.A. Sarhan, A.K. Hussein, H. Arima
    J. Drug Target, in press (2014).
  44. Potential use of glucuronylglucosyl-b-cyclodextrin/dendrimer conjugate (G2) as a siRNA carrier for the treatment of familial amyloidotic polyneuropathy T. Anno, T. Higashi, Y. Hayashi, K. Motoyama, H. Jono, Y. Ando, H. Arima
    J. Drug Target., in press (2014).
  45. Potential Use of a Megamolecular Polysaccharide Sacran as a Hydrogel-based Sustained Release System K. Motoyama, Y. Tanida, K. Hata, T. Hayashi, T. Higashi, Y. Ishitsuka, Y. Kondo, T. Irie, S. Kaneko, H. Arima
    Chem. Pharm. Bull., 62(7), 636-641 (2014).
  46. Potential Use of the Complex of Doxorubicin with Folate-conjugated Methyl-b-cyclodextrin for Tumor-selective Cancer Chemotherapy. K. Motoyama, R. Onodera, A. Okamatsu, T. Higashi, R. Kariya, S. Okada, H. Arima
    J. Drug. Target., 22(3), 211-219 (2014).
  47. Improvement of Pharmaceutical Properties of Insulin through Conjugation with Glucuronylglucosyl-b-cyclodextrin T. Hirotsu, T. Higashi, K. Motoyama, F. Hirayama, K. Uekama, H. Arima
    J. Incl. Phenom. Macro. Chem., 80(1-2), 107-112 (2014).
  48. Involvement of Autophagy in Antitumor Activity of Folate-appended Methyl-b-cyclodextrin . R. Onodera, K. Motoyama, N. Tanaka, A. Ohyama, A. Okamatsu, T. Higashi, R. Kariya, S. Okada, H. Arima
    Sci. Rep., 4(4417), 1-8 (2014).
  49. Potential Use of Niosomal Hydrogel as an Ocular Delivery System for Atenolol. I.I. Abu Hashim, M.S. El-dahan, R.M. Yusif, A.-E.H. Abd-ElGawad, H. Arima
    Biol. Pharm. Bull., 37(4), 541-551 (2014).
  50. Influence of Npc1 genotype on the toxicity of hydroxypropyl-b-cyclodextrin, a potentially therapeutic agent, in Niemann-Pick Type C disease models. Y. Tanaka; Y. Ishitsuka, Y. Yamada; Y. Kondo, T. Takeo, N. Nakagata, T. Higashi, K. Motoyama; H. Arima, M. Matsuo, K. Higaki, K. Ohno, T. Irie
    Mol. Genet. Metab. Rep., 1(1), 19-30 (2014). (2014).
  51. Design and evaluation of folate-appended a-, b- and g-cyclodextrins having a caproic acid as a tumor selective antitumor drug carrier in vitro and in vivo. A. Okamatsu, K. Motoyama, R. Onodera, T. Higashi, T. Koshigoe, Y. Shimada, K. Hattori, T. Takeuchi, H. Arima
    Biomacromolecules, 14(12), 4420-4428 (2013).
  52. Sugar-appended polyamidoamine dendrimer conjugates with cyclodextrins as cell-specific non-viral vectors H. Arima, K. Motoyama, T. Higashi
    Adv. Drug Deliv. Rev., 65(9), 1204-1214 (2013).
  53. Reply: Lung toxicity of hydroxyl-b-cyclodextrin infusion. M. Matsuo, H. Arima, T. Irie
    Mol. Genet. Metab., 109(2), 233 (2013).
  54. Involvement of Cholesterol Depletion from Lipid Rafts in Apoptosis Induced by Methyl-b-cyclodextrin R. Onodera, K. Motoyama, A. Okamatsu, T. Higashi, R. Kariya, S. Okada, H. Arima
    Int. J. Pharm., 452(1-2), 116-123 (2013).
  55. Design and evaluation of polyamidoamine dendrimer conjugate with PEG, a-cyclodextrin and lactose as a novel hepatocyte-selective gene carrier in vitro and in vivo Y. Hayashi, T. Higashi, K. Motoyama, Y. Mori, H. Jono, Y. Ando, H. Arima
    J. Drug. Target., 21(5), 487-496 (2013).
  56. Folate-appended b-cyclodextrin as a promising tumor targeting carrier for antitumor drugs in vitro and in vivo A. Okamatsu, K. Motoyama, R. Onodera, T. Higashi, T. Koshigoe, Y. Shimada, K. Hattori, T. Takeuchi, H. Arima
    Bioconjug. Chem., 24(4), 724-733 (2013).
  57. Potential Use of Folate-appended Methyl-b-Cyclodextrin as an Anticancer Agent R. Onodera, K. Motoyama, A. Okamatsu, T. Higashi, H. Arima
    Sci. Rep., 3, 1104, 1-9 (2013).
  58. Insulin Receptor Activation through Its Accumulation in Lipid Rafts by Mild Electrical Stress. S. Morino-Koga, S. Yano, T. Kondo, Y. Shimauchi, S. Matsuyama, Y. Okamoto, M.A. Suico, T. Koga, T. Sato, T. Shuto, H. Arima, I. Wada, E. Araki, H. Kai.
    J. Cell. Physiol., 228(2), 439-446 (2013).
  59. Folate-PEG-appended Dendrimer Conjugate with a-Cyclodextrin as a Novel Cancer Cell-selective siRNA Delivery Carrier H. Arima, A. Yoshimatsu, H. Ikeda, A. Ohyama, K. Motoyama, T. Higashi, A. Tsuchiya, T. Niidome, Y. Katayama, K. Hattori, T. Takeuchi
    Mol. Pharm., 9(9), 2591-2604 (2012).
  60. Evaluation of photodynamic activity of C(60)/2-hydroxypropyl-b-cyclodextrin nanoparticles. D. Iohara, M. Hiratsuka, F. Hirayama, K. Takeshita, K. Motoyama, H. Arima, K. Uekama
    J. Pharm. Sci., 101(9), 3390-3397 (2012).
  61. Cyclodextrin/poly(ethylene glycol) Polypseudorotaxane Hydrogels as a Promising Sustained Release System for Lysozyme T. Higashi, A. Tajima, K. Motoyama, H. Arima
    J. Pharm. Sci., 101(8), 2891-2899 (2012).
  62. Potential Use of Lactosylated Dendrimer (G3)/ a-cyclodextrin Conjugates as Hepatocyte-specific siRNA Carriers for the Treatment of Familial Amyloidotic Polyneuropathy Y. Hayashi, Y. Mori, S. Yamashita, K. Motoyama, T. Higashi, H. Jono, Y. Ando, H. Arima
    Mol. Pharm., 9(6), 1645-1653 (2012).
  63. Potential use of glucuronylglucosyl-b-cyclodextrin as a novel therapeutic tool for familial amyloidotic polyneuropathy H. Jono, T. Anno, K. Motoyama, Y. Misumi, M. Tasaki, T. Oshima, Y. Mori, M. Mizuguchi, M. Ueda, S. Shinriki, M. Shono, K. Obayashi, H. Arima, Y. Ando
    Amyloid, 19(S1), 50-52 (2012).
  64. Systemic delivery of transthyretin siRNA mediated by lactosylated dendrimer/a-cyclodextrin conjugates into hepatocyte for familial amyloidotic polyneuropathy therapy. Y. Hayashi, Y. Mori, T. Higashi, K. Motoyama, H. Jono, D.W. Sah, Y. Ando, H. Arima
    Amyloid, 19(S1), 47-49 (2012).
  65. Potential Use of Folate-polyethylene glycol (PEG)-Appended Dendrimer (G3) Conjugate with a-Cyclodextrin as DNA Carriers to Tumor Cells H. Arima, M. Arizono, T. Higashi, A. Yoshimatsu, H. Ikeda, K. Motoyama, K. Hattori, T. Takeuchi, F. Hirayama, K. Uekama
    Cancer Gene Ther., 19(5), 358-366 (2012).
  66. Cyclodextrin-Induced Change in Crystal Habit of Acetylsalicylic Acid in Aqueous Solution D. Iohara, K. Yoshida, K. Yamaguchi, M. Anraku, K. Motoyama, H. Arima, K. Uekama, F. Hirayama
    Crystal Growth & Design, 12(4), 1985-1991 (2012).
  67. Possible Enhancing Mechanisms for Gene Transfer Activity of Glucuronylglucosyl-b-cyclodextrin/dendrimer Conjugate (G2) T. Anno, T. Higashi, K. Motoyama, F. Hirayama, K. Uekama, H. Arima
    Int. J. Pharm., 426(1-2), 239-247 (2012).
  68. Polypseudorotaxanes of Pegylated a-Cyclodextrin/Polyamidoamine Dendrimer Conjugate with Cyclodextrins as a Sustained Release System for DNA
    K. Motoyama, K. Hayashida, T. Higashi, H. Arima
    Bioorg. Med. Chem., 20(4), 1425-1433 (2012).
  69. Potential use of glucuronylglucosyl-b-cyclodextrin/dendrimer conjugate (G2) as a DNA carrier in vitro and in vivo T. Anno, T. Higashi, K. Motoyama, F. Hirayama, K. Uekama, H. Arima
    J. Drug Target.20(3), 272-280 (2012).
  70. Peak-less Hypoglycemic Effect of Insulin Glargine by Complexation with Maltosyl-b-cyclodextrin. K. Uehata, T. Anno, K. Hayashida, T. Higashi, K. Motoyama, F. Hirayama, K. Uekama, H. Arima
    Int. J. Pharm., 422(1-2), 33-39 (2012).
  71. Effects of Selected Anionic b-Cyclodextrins on Persistence of Blood Glucose Lowering by Insulin Glargine after Subcutaneous Injection to Rats. K. Uehata, T. Anno, K. Hayashida, K. Motoyama, T. Higashi, F. Hirayama, N. Ono , J.D. Pipkin, K. Uekama, H. Arima
    J. Drug Delivery, 2011, 1-9 (2011).
  72. Inhibitory Effect of siRNA Complexes with Polyamidoamine Dendrimer/a-Cyclodextrin Conjugate (Generation 3, G3) on Endogenous Gene Expression
    73. H. Arima, T. Tsutsumi, A. Yoshimatsu, H. Ikeda, K. Motoyama, T. Higashi, F. Hirayama, K. Uekama Eur. J. Pharm. Sci.44(3), 375-384 (2011).
  73. Some pharmaceutical and inclusion properties of 2-hydroxybutyl-b-cyclodextrin derivative.
    T. Ishiguro, E. Morishita, D. Iohara, F. Hirayama, K. Wada, K. Motoyama, H. Arima, K. Uekama
    Int. J. Pharm., 419(1-2), 161-169 (2011).
  74. Effect of Sulfobutyl ether-b-cyclodextrin on Bioavailability of Insulin Glargine and Blood Glucose Level after Subcutaneous Injection to Rats
    K. Uehata, T. Anno, K. Hayashida, K. Motoyama, F. Hirayama, N. Ono, J.D. Pipkin, K. Uekama, H. Arima
    Int. J. Pharm., 419(1-2), 71-76 (2011).
  75. Effect of cyclodextrins on Transthyretin amyloid formation in Transthyretin-related amyloidosis
    H. Jono, T. Anno, Y. Misumi, Y. Mori, K. Motoyama, M. Ueda, Y. Horibata, M. Shono, K. Obayashi, H. Arima, Y. Ando
    Amyloid, 18(SUPPL. 1), 58-59 (2011).
  76. Design and Evaluation of Folate-appended Methyl-b-cyclodextrin as a New Antitumor Agent
    R. Onodera, K. Motoyama, H. Arima
    J. Incl. Phenom. Macrocycl. Chem., 70, 321-326 (2011).
  77. In Vitro Gene Delivery Mediated by Lactosylated Dendrimer (generation 3, G3)/a-Cyclodextrin Conjugates into Hepatocytes
    K. Motoyama, Y. Mori, S. Yamashita, Y. Hayashi, H. Jono, Y. Ando, F. Hirayama, K. Uekama, H. Arima
    J. Incl. Phenom. Macrocycl. Chem., 70, 333-338 (2011).
  78. Preparation and Evaluation of Polyamidoamine Dendrimer (G2)/Branched-b-cyclodextrin Conjugate as a Novel Gene Transfer Carrier
    T. Anno, K. Motoyama, T. Higashi, F. Hirayama, K. Uekama, H. Arima
    J. Incl. Phenom. Macrocycl. Chem., 70, 339-344 (2011).
  79. Cyclodextrin, a novel therapeutic tool for suppressing amyloidogenic transthyretin misfolding in transthyretin-related amyloidosis.
    H. Jono, T. Anno, K. Motoyama, Y. Misumi, M. Tasaki, T. Oshima, Y. Mori, M. Mizuguchi, M. Ueda, M. Shono, K. Obayashi, H. Arima, Y. Ando
    Biochem. J., 437(1), 35-42 (2011).
  80. Improvement of Some Physicochemical Properties of Arundic Acid, (R)-(-)-2-Propyloctanonic Acid, by Complexation with Hydrophilic Cyclodextrins.
    Y. Miyamoto, M. Nakahara, K. Motoyama, T. Ishiguro, Y. Oda, T. Yamanoi, I. Okamoto, A. Yagi, H. Nishimura, F. Hirayama, K. Uekama, H. Arima
    Int. J. Pharm., 413(1-2), 63-72 (2011).
  81. Involvement of lipid rafts in macrophage apoptosis induced by cationic liposomes.
    M. Arisaka, K. Takano, Y. Negishi, H. Arima, Y. Aramaki.
    Arch. Biochem. Biophys., 508, 72-77 (2011).
  82. Potential Use of Polypseudorotaxanes of Pegylated Polyamidoamine Dendrimer with Cyclodextrins as Novel Sustained Release Systems for DNA
    K. Motoyama, K. Hayashida, H. Arima
    Chem. Pharm. Bull., 59(4), 476-479 (2011).
  83. Reduction of Bitterness of Antihistaminic Drugs by Complexation with b-Cyclodextrins
    N. Ono (nee Yoshida), Y. Miyamoto, T. Ishiguro, K. Motoyama, F. Hirayama, D. Iohara, H. Seo, S. Tsuruta, H. Arima, K. Uekama
    J. Pharm. Sci., 100(5), 1935-1943 (2011).
  84. In Vitro Gene Delivery Mediated by Asialofetuin-appended Cationic Liposomes Associated with g-Cyclodextrin into Hepatocytes
    K. Motoyama, Y. Nakashima, Y. Aramaki, F. Hirayama, K. Uekama, H. Arima
    J. Drug Delivery, 2011, 1-13 (2011).
  85. In Vitro and In Vivo Gene Delivery Mediated by Lactosylated Dendrimer/a-Cyclodextrin Conjugates (G2) into Hepatocytes.
    H. Arima, S. Yamashita, Y. Mori, Y. Hayashi, K. Motoyama, K. Hattori, T. Takeuchi, H. Jono, Y. Ando, F. Hirayama, K. Uekama
    J. Control. Release, 146(1), 106-117 (2010).
  86. Potential Use of Iontophoresis for Transdermal Delivery of NF-kB Decoy Oligonucleotides.
    I.I. Abu Hashim, K. Motoyama, A.E. Abd-Elgawad, M.H. El-Shabouri, T.M. Borg, H. Arima.
    Int. J. Pharm., 393(1-2), 127-134 (2010).
  87. Inhibition of Human Tumor Cell Proliferation by the Telomerase Inhibitor TELIN
    Y. Kakiuchi, M. Oyama, M. Nakatake, Y. Okamoto, H. Kai, H. Arima, H. Murofushi, K. Murakami-Murofuchi
    Cytologia, 75(2), 177-183 (2010).
  88. Potential use of g-cyclodextrin polypseudorotaxane hydrogels as an injectable sustained release system for insulin.
    I.I. Abu Hashim, T. Higashi, T. Anno, K. Motoyama, A.E. Abd-Elgawad, M.H. El-Shabouri, T.M. Borg, H. Arima.
    Int. J. Pharm., 392(1-2), 83-91 (2010).
  89. Crystallization and Polymorphic Transition of Chlorpropamide in Aqueous 2-Hydroxybutyl-b-cyclodextrin Solution
    T. Ishiguro, F. Hirayama, D. Iohara, H. Arima, K. Uekama
    Eur. J. Pharm. Sci., 39(4), 248-255 (2010).
  90. 5-Fluorouracil acetic acid/b-cyclodextrin conjugates: Drug release behavior in enzymatic and rat cecal media
    K. Udo, K. Hokonohara, K. Motoyama, H. Arima, F. Hirayama, K. Uekama
    Int. J. Pharm., 388(1-2), 95-100 (2010).
  91. A Plasma Protein Indistinguishable from Ribosomal Protein S19: Conversion to a Monocyte Chemotactic Factor by a Factor XIIIa-Catalyzed Reaction on Activated Platelet Membrane Phosphatidylserine in Association with Blood Coagulation
    U. Semba, J. Chen, Y. Ota, N. Jia, H. Arima, H. Nishiura, T. Yamamoto
    Am. J. Pathol., 176(3), 1542-1551 (2010).
  92. Potential Use of 2-Hydroxypropyl-β-cyclodextrin for Preparation of Orally Disintegrating Tablets Containing dl-α-Tocopherol Acetate, an Oily Drug
    K. Motoyama, K. Nagatomo, O.A.E. Soliman, F. Hirayama, K. Uekama, H. Arima
    Chem. Pharm. Bull., 57(11), 1206-1212 (2009).
  93. Involvement of PI3K-Akt-Bad pathway in apoptosis induced by 2,6-di-O-methyl-β-cyclodextrin, not 2,6-di-O-methyl-α-cyclodextrin, through cholesterol depletion from lipid rafts on plasma membranes in cells
    K. Motoyama, K. Kameyama, R. Onodera, N. Araki, F. Hirayama, K. Uekama, H. Arima
    Eur. J. Pharm. Sci., 38(3), 249-261 (2009).
  94. Preparation of Four Types of Coenzyme Q10/g-Cyclodextrin Supramolecular Complexes and Comparison of Their Pharmaceutical Properties
    T. Higashi, K. Nishimura, A. Yoshimatsu, H. Ikeda, K. Arima, K. Motoyama, F. Hirayama, K. Uekama, H. Arima
    Chem. Pharm. Bull., 57(9), 965-970 (2009).
  95. Slow-release System of Pegylated Lysozyme Utilizing Formation of Polypseudorotaxanes with Cyclodextrins.
    T. Higashi, F. Hirayama, S. Yamashita, S. Misumi, H. Arima, K. Uekama
    Int. J. Pharm., 374(1-2), 26-32 (2009).
  96. Polypseudorotaxane Formation of Randomly-pegylated Insulin with Cyclodextrins: Slow Release and Resistance to Enzymatic Degradation.
    T. Higashi, F. Hirayama, S. Misumi, K. Motoyama, H. Arima, K. Uekama
    Chem. Pharm. Bull., 57(5), 541-544 (2009).
  97. Involvement of Lipid Rafts of Rabbit Red Blood Cells in Morphological Changes Induced by Methylated β-Cyclodextrins.
    K. Motoyama, H. Toyodome, R. Onodera, T. Irie, F. Hirayama, K. Uekama, H. Arima
    Biol. Pharm. Bull., 32(4), 700-705 (2009).
  98. Inhibitory Effects of 2,6-Di-O-methyl-a-cyclodextrin on Poly I:C Signaling in Macrophages
    K. Motoyama, Y. Hashimoto, F. Hirayama, K. Uekama, H. Arima
    Eur. J. Pharm. Sci., 36, 285-291 (2009).
  99. Recent Findings of Polyamidoamine Dendrimer Conjugates with Cyclodextrins as DNA and Small-interfering RNA Carriers
    H. Arima, K. Motoyama, F. Hirayama, K. Uekama
    Proc. 14th Int. Cyclodextrins Symposium, 33-41 (2008).
  100. Synthesis and Evaluation of Folate-Modified Cyclodextrins
    K. Hattori, T. Koshigoe, T. Takeuchi, R. Onodera, K. Muraki, H. Akiyama, H. Arima, M. Arizono, K. Uekama
    Proc. 14th Int. Cyclodextrins Symposium, 94-97 (2008).
  101. Folate-PEG-Appended Dendrimer Conjugate with a-Cyclodextrin as a Novel Cancer Cell-Selective Gene Transfer Carrier.
    A. Yoshimatsu, M. Arizono, K. Motoyama, K. Hattori, T. Takeuchi, F. Hirayama, K. Uekama, H. Arima
    Proc. 14th Int. Cyclodextrins Symposium, 276-281 (2008).
  102. Inhibitory Effects of 2,6-di-O-methyl-a-Cyclodextrin on Polyinosinic-Polycytidylic Acid Signaling in Macrophages
    K. Motoyama, Y. Hashimoto, F. Hirayama, K. Uekama, H. Arima
    Proc. 14th Int. Cyclodextrins Symposium, 282-286 (2008).
  103. Design and evaluation of polypseudorotaxanes of pegylated insulin with cyclodextrins as sustained release system
    T. Higashi, F. Hirayama, S. Misumi, H. Arima, K. Uekama
    Biomaterial, 29, 3866-3871 (2008).
  104. Potential use of Polyamidoamine Dendrimer/a-Cyclodextrin Conjugate (generation 3, G3) as a Novel Carrier for Short Hairpin RNA-Expressing Plasmid DNA
    T. Tsutsumi, F. Hirayama, K. Uekama, H. Arima
    J. Pharm. Sci., 97 (8), 3022-3034 (2008).
  105. Pseudorotaxane-like supramolecular complex of coenzyme Q10 with g-cyclodextrin formed by solubility method
    K. Nishimura, T. Higashi, A. Yoshimatsu, F. Hirayama, K. Uekama, H. Arima.
    Chem. Pharm. Bull., 56(5), 701-706 (2008).
  106. Preparation of amorphous indomethacin from aqueous 2,6-di-O-methyl-b-cyclodextrin solution
    D. Iohara, F. Hirayama, T. Ishiguro, H. Arima, K. Uekama.
    Int. J. Pharm., 354(1-2), 70-76 (2008).
  107. Methyl-b-Cyclodextrin Improves Fertilizing Ability of C57BL/6 Mouse Sperm after Freezing and Thawing by Facilitating Cholesterol Efflux from the Cells.
    T. Takeo, T. Hoshii, Y. Kondo, H. Toyodome, H. Arima, K.I. Yamamura, T. Irie, N. Nakagata.
    Biol. Reprod., 78(3), 546-551 (2008).
  108. Improved Stability of OPALMON Tablets under Humid Conditions IV: Effect of polysaccharides and disintegrants on the stability and dissolution property of OPALMON Tablets
    N. Sekiya, A. Nishiwaki, A. Nishiura, M. Yamamoto, K. Takeda, D. Iohara, F. Hirayama, H. Arima, K. Uekama
    Chem. Pharm. Bull., 56(1), 7-11 (2008).
  109. Improvement of dissolution properties of a new Helicobacter pylori eradicating agent (TG44) by inclusion complexation with b-cyclodextrin
    K. Anzai, J. Mizoguchi, T. Yanagi, F. Hirayama, H. Arima, K. Uekama
    Chem. Pharm. Bull. , 55(10), 1466-1470 (2007).
  110. Evaluation of polyamidoamine dendrimer/α-cyclodextrin conjugate (generation 3, G3) as a novel carrier for small interfering RNA (siRNA)
    T. Tsutsumi, F. Hirayama, K. Uekama, H. Arima
    J. Control. Release, 119(3), 349-359 (2007).
  111. Polypseudorotaxanes of pegylated insulin with cyclodextrins: Application to sustained release system
    T. Higashi, F. Hirayama, H. Arima, K. Uekama
    Bioorg. Med. Chem. Lett., 17(7), 1871-1874 (2007).
  112. Enhancement of gene transfer activity mediated by mannosylated dendrimer/α-cyclodextrin conjugate (generation 3, G3)
    H. Arima, Y. Chihara, M. Arizono, S. Yamashita, K. Wada, F. Hirayama, K. Uekama
    J. Control. Release, 116(1), 64-74 (2006).
  113. Effects of Cyclodextrins on Chemically- and Thermally-induced Unfolding and Aggregation of Lysozyme and Basic Fibroblast Growth Factor
    S. Tavornvipas, F. Hirayama, S. Takeda, H. Arima, K. Uekama
    J. Pharm. Sci. , 95(12), 2722-2729 (2006). abstract
  114. Enhancement of oral bioavailability of coenzyme Q10 by the complexation with γ-cyclodextrin in healthyl adult volunteers
    K. Terao, D. Nakata, H. Fukumi, G. Schmid, H. Arima, F. Hirayama, K. Uekama
    Nutr. Res. , 26, 503-508 (2006). abstract
  115. Effect of 2,6-Di-O-methyl-α-cyclodextrin on Hemolysis and Morphological Change in Rabbit's Red Blood Cells
    K. Motoyama, H. Arima, H. Toyodome, T. Irie, F. Hirayama, K. Uekama
    Eur. J. Pharm. Sci. , 29(2), 111-119 (2006). abstract
  116. Enhanced Bioavailability of a New Thiazolidine Derivative FPFS-410, an Antidiabetic and Lipid-lowering Drug, after Oral Administration of Its Hydroxypropyl-β-cyclodextrin Complex to Bile Duct-cannulated Rats
    T. Hara, H. Arima, F. Hirayama, K. Uekama
    J. Pharm. Sci. , 95(8), 1771-1782 (2006). abstract
  117. Enhancement of Antitumor Effect of Doxorubicin by Its Complexation with γ-Cyclodextrin in Pegylated Liposomes
    H. Arima, Y. Hagiwara, F. Hirayama, K. Uekama
    J. Drug Target., 14(4), 225-232 (2006). abstract
  118. Selective Crystallization of Metastable Form IV Polymorph of Tolbutamide in the Presence of 2,6-Di-O-methyl-β-cyclodextrin in Aqueous Solution
    Y. Sonoda, F. Hirayama, H. Arima, Y. Yamaguchi, W. Saenger, K. Uekama
    Crystal Growth & Design , 6, 1181-1185 (2006). abstract
  119. Enhanced Dissolution and Oral Bioavailability of Coenzyme Q10 in Dogs by Inclusion Complexation with γ-Cyclodextrin
    X.Y. Gao, K. Nishimura, F. Hirayama, H. Arima, K. Uekama, G. Schmid, K. Terao, D. Nakata, H. Fukumi
    Asian J. Pharm. Sci. ,1(2), 95-102 (2006).
  120. Two-dimensional (13)C-(1)H heteronuclear correlation NMR spectroscopic studies for the inclusion complex of cyclomaltoheptaose (β-cyclodextrin) with a new Helicobacter pylori eradicating agent (TG44) in the amorphous state.
    K. Anzai, H. Kono, J.I. Mizoguchi, T. Yanagi, F. Hirayama, H. Arima, K. Uekama
    Carbohydr. Res., 341(4), 499-506 (2006). abstract
  121. Cyclodextrin-based isolation of Ostwald's metastable polymorphs occurring during crystallization.
    Y. Sonoda, F. Hirayama, H. Arima, Y. Yamaguchi, W. Saenger, K. Uekama
    Chem. Commun., (5), 517-519 (2006). abstract
  122. Preparation and Pharmaceutical Evaluation of Liposomes Entrapping Salicylic Acid/γ-Cyclodextrin Conjugate
    Y. Hagiwara, H. Arima, Y. Miyamoto, F. Hirayama, K. Uekama
    Chem. Pharm. Bull., 54(1), 26-32 (2006). abstract
  123. Improvement of Solubility and Oral Bioavailability of 2-(N-Cyanoimino)-5-{(E)-4-styrylbenzylidene}-4- oxothiazolidine (FPFS-410) with Antidiabetic and Lipid-lowering Activities in Dogs by 2-Hydroxypropyl-β-cyclodextrin
    T. Hara, F. Hirayama, H. Arima, Y. Yamaguchi, K. Uekama
    Chem. Pharm. Bull., 54(3), 344-349 (2006). abstract
  124. Prolonged Retention of Doxorubicin in Tumor Cells by Encapsulation of γ-Cyclodextrin Complex in Pegylated Liposomes
    Y. Hagiwara, H. Arima, F. Hirayama, K. Uekama
    J. Incl. Phenom. Macrocycl. Chem., 56, 65-68 (2006).
  125. Prominent Solubilizing Effect of 2-Hydoxypropyl-β-cyclodextrin on a New Thiazolidine Derivative (FPFS-410) with Antidiabetic and Lipid-lowering Activities through Inclusion Complex Formation
    T. Hara, F. Hirayama, H. Arima, Y. Yamaguchi, K. Uekama
    J. Incl. Phenom. Macrocycl. Chem., 56, 135-139 (2006).
  126. Improvement of Dispersion and Release Properties of Nifedipine in Suppositories by Complexation with 2-Hydroxypropyl-β-cyclodextrin
    K. Nishimura, R. Hidaka, F. Hirayama, H. Arima, K. Uekama
    J. Incl. Phenom. Macrocycl. Chem., 56, 85-88 (2006).
  127. Inhibitory Effects of 2,6-Di-O-methyl-3-O-acetyl-β-cyclodextrins with Various Degrees of Substitution of Acetyl Group on Macrophage Activation and Endotoxin Shock Induced by Lipopolysaccharide.
    K. Motoyama, H. Arima, F. Hirayama, K. Uekama
    J. Incl. Phenom. Macrocycl. Chem., 56, 75-79 (2006).
  128. Serum-resistant Gene Transfer Activity of Mannosylated Dendrimer/α-Cyclodextrin Conjugate (G3)
    Y. Chihara, H. Arima, M. Arizono, K. Wada, F. Hirayama, K. Uekama
    J. Incl. Phenom. Macrocycl. Chem., 56, 89-93 (2006).
  129. Potential Use of Dendrimer/α-Cyclodextrin Conjugate as a Novel Carrier for Small Interfering RNA (siRNA)
    T. Tsutsumi, H. Arima, F. Hirayama, K. Uekama
    J. Incl. Phenom. Macrocycl. Chem., 56, 81-84 (2006).
  130. Membrane-anchored CD14 is required for LPS-induced TLR4 endocytosis in TLR4/MD-2/CD14 overexpressing CHO cells
    T. Shuto, K. Kato, Y. Mori, S. Viriyakosol, M. Oba, T. Furuta, T. Okiyoneda, H. Arima, M.A. Suico, H. Kai
    Biochem. Biophys. Res. Commun., 338, 1402-1409 (2005). abstract
  131. Inhibitory effects of dimethylacetyl-β-cyclodextrin on lipopolysaccharide-induced macrophage activation and endotoxin shock in mice
    H. Arima, K. Motoyama, A. Matsukawa, Y. Nishimoto, F. Hirayama, K. Uekama
    Biochem. Pharmacol.,70(10), 1506-1517 (2005).
  132. Improvement of gene delivery mediated by mannosylated dendrimer/α-cyclodextrin conjugates
    K. Wada, H. Arima, T. Tsutsumi, Y. Chihara, K. Hattori, F. Hirayama, K. Uekama
    J. Control. Rel.,104(2), 397-414 (2005). abstract
  133. Involvement of CD14 in the inhibitory effects of dimethyl-α-cyclodextrin on lipopolysaccharide signaling in macrophages
    K. Motoyama, H. Arima, Y. Nishimoto, K. Miyake, F. Hirayama, K. Uekama
    FEBS Lett., 579(7), 1707-1714 (2005). abstract
  134. Enhancing Effects of Galactosylated Dendrimer/α-Cyclodextrin Conjugates on Gene Transfer Efficiency
    K. Wada, H. Arima, T. Tsutsumi, F. Hirayama, K. Uekama
    Biol. Pharm. Bull., 28(3), 500-505 (2005). abstract
  135. Pharmaceutical Application of Cyclodextrins as Multi-functional Drug Carrier
    K. Uekama
    Yakugaku Zasshi,124(12), 909-935 (2004). abstract
  136. Effects of Hydrophilic Cyclodextrins on Aggregation of Recombinant Human Growth Hormone
    S. Tavornvipas, S. Tajiri, F. Hirayama, H. Arima, K. Uekama
    Pharm. Res.,21 2369-2376 (2004). abstract
  137. Applicability of (SBE)(7m)-β-CD in controlled-porosity osmotic pump tablets (OPTs).
    K. Okimoto, Y. Tokunaga, R. Ibuki, T. Irie, K. Uekama, R.A. Rajewski, V.J. Stella
    Int. J. Pharm., 286 (1-2) 81-88 (2004). abstract
  138. Effects of 2-Hydroxypropyl-β-cyclodextrin on Polymorphic Transition of Chlorpropamide in Various Conditions: Temperature, Humidity and Moulding Pressure.
    Y. Sonoda, F. Hirayama, H. Arima, K. Uekama
    J. Incl. Phenom. Macrocycl. Chem., 50 (4) 73-77 (2004). abstract
  139. Design and evaluation of cyclodextrin-based drug formulation.
    K. Uekama
    Chem. Pharm. Bull., 52(8), 900-915 (2004). abstract
  140. Polyfection as Nonviral Gene Transfer Method:Design of Novel Nonviral Vector Using α-Cyclodextrin.
    H. Arima
    Yakugaku Zasshi, 124(7), 451-464 (2004). abstract
  141. NMR Spectroscopic Characterization of Metoprolol/Cyclodextrin Complexes in Aqueous Solution: Cavity Size Dependency.
    Y. Ikeda, F. Hirayama, H. Arima, K. Uekama, Y. Yoshitake, K. Harano
    J. Pharm. Sci., 93(7), 1659-1671 (2004). abstract
  142. Potential Use of 2-Hydroxypropyl-β-cyclodextrin as a Release Modifier of a Water-soluble Drug, Metoprolol Tartrate, from Ethylcellulose Tablets.
    Y. Ikeda, S. Motoune, M. Ono, H. Arima, F. Hirayama, K. Uekama
    J. Drug Del. Sci. Tech., 14(1), 69-76 (2004). abstract
  143. Contribution of Cholesterol and Phospholipids to Inhibitory Effect of Dimethyl-β-cyclodextrin on Efflux Function of P-glycoprotein and Multidrug Resistance-associated Protein 2 (MRP2) in Vinblastine-resistant Caco-2 Cell Monolayers.
    H. Arima, K. Yunomae, T. Morikawa, F. Hirayama, K. Uekama
    Pharm. Res., 21(4), 625-634 (2004). abstract
  144. Improvement of dermatitis by iontophoretically delivered antisense oligonucleotides for interleukin-10 in NC/Nga mice.
    T. Sakamoto, E. Miyazaki, Y. Aramaki, H. Arima, M. Takahashi, Y. Kato, M. Koga, S. Tsuchiya
    Gene Ther., 11(3), 317-324 (2004). abstract
  145. In Vitro and In Vivo Gene Transfer by an Optimized α-Cyclodextrin Conjugate with Polyamidoamine Dendrimer.
    Fumihiro Kihara; Hidetoshi Arima; Toshihito Tsutsumi; Fumitoshi Hirayama; Kaneto Uekama
    Bioconjugate Chem, 14(2), 342-350 (2003). abstract
  146. Involvement of cholesterol in the inhibitory effect of dimethyl-β-cyclodextrin on P-glycoprotein and MRP2 function in Caco-2 cells.
    Kiyokazu Yunomae; Hidetoshi Arima; Fumitoshi Hirayama; Kaneto Uekama
    FEBS Lett., 536(1-3), 225-231 (2003) . abstract
  147. Efficient Gene Transfer to Hepatoblastoma Cells through Asialoglycoprotein Receptor and Expression under the Control of the Cyclin A Promoter.
    Y. Aramaki, I. Lee, H. Arima, T. Sakamoto, Y. Magami,T. Yoshimoto, F. Moriyasu, J. Mizuguchi, Y. Koyanagi, T. Nikaido, S. Tsuchiya.
    Biol. Pharm. Bull., 26(3), 357-360 (2003). abstract
  148. Inhibitory Effect of Sulfobutyl Ether β-Cyclodextrin on DY-9760e-Induced Cellular Damage: In Vitro and In Vivo Studies.
    Y. Nagase, H. Arima, K. Wada, T. Sugawara, H. Satoh, F. Hirayama, K. Uekama.
    J. Pharm. Sci., 92(12), 2475-2483 (2003). abstract
  149. Intradermal Delivery of Antisense Oligonucleotides by the Pulse Depolarization Iontophoretic System.
    Y. Aramaki, H. Arima, M. Takahashi, E. Miyazaki, T. Sakamoto, S. Tsuchiya
    Biol. Pharm. Bull., 26, 1461-1466 (2003). abstract
  150. Recent Aspects of Pharmaceutical Application of Cyclodextrins.
    Kaneto Uekama
    J. Incl. Phenom. Macrocycl. Chem. , 44(2), 3-7 (2002). abstract
  151. Model Analysis for Oral Absorption of a Drug/Cyclodextrin Complex Involving Competitive Inclusion Complexes.
    Naomi Ono; Fumitoshi Hirayama; Hidetoshi Arima; Kaneto Uekama; J. Howard Rytting
    J. Incl. Phenom. Macrocycl. Chem. , 44(2), 93-96 (2002). abstract
  152. Inclusion Complexation of a Seleno-Organic Antioxidant, Ebselen, with Cyclodextrins in Aqueous Solution.
    Yukihiko Nagase; Norio Suzuki; Hitoshi Yamauchi; Sunyong Kim; Koki Wada; Hidetosh Arima; Fumitoshi Hirayama; Kaneto Uekama
    J. Incl. Phenom. Macrocycl. Chem. , 44(2), 107-110 (2002). abstract
  153. Effect of 2-Hydroxypropyl-β-cyclodextrin on Release Rate of Metoprolol from Ternary Metoprolol/2-hydroxypropyl-β-cyclodextrin/Ethylcellulose Tablets.
    Yoichi Ikeda; Sohko Motoune; Aya Marumoto; Yoh Sonoda; Fumitoshi Hirayama; Hidetoshi Arima; Kaneto Uekama
    J. Incl. Phenom. Macrocycl. Chem. , 44(2), 141-144 (2002). abstract
  154. Prolonged Plasma Levels of Ketoprofen after Oral Administration of Its α-Cyclodextrin Conjugate/Ethylcellulose Dispersion in Rats .
    Fumitoshi Hirayama; Makoto Kamada; Hideki Yano; Koichi Udo; Hidetoshi Arima; Kaneto Uekama
    J. Incl. Phenom. Macrocycl. Chem. , 44(2), 159-161 (2002). abstract
  155. Cell-Specific Gene Transfer by α-Cyclodextrin Conjugates with Mannosylated Polyamidoamine.
    Hidetoshi Arima; Koki Wada; Fumihiro Kihara; Toshihito Tsutsumi; Fumitoshi Hirayama; Kaneto Uekama
    J. Incl. Phenom. Macrocycl. Chem. , 44(2), 361-364 (2002). abstract
  156. Some Pharmaceutical Properties of a New Branched Cyclodextrin, 6- O-α-(4- O- α-D-Glucuronyl)-D-glucosyl β-cyclodextrin.
    Sumitra Tavornvipas; Hidetoshi Arima; Fumitoshi Hirayama; Kaneto Uekama; Toshihiro Ishiguro; Masahide Oka; Kenichi Hamayasu; Hitoshi Hashimoto
    J. Incl. Phenom. Macrocycl. Chem. , 44(2), 391-394 (2002). abstract
  157. Protective effect of sulfobutyl ether β-cyclodextrin on DY-9760e-induced hemolysis in vitro
    Y. Nagase, M. Hirata, H. Arima, S. Tajiri, Y. Nishimoto, F. Hirayama, T. Irie, K. Uekama:
    J. Pharm Sci., 91, 2382-2389 (2002). abstract
  158. Effects of Structure of Polyamidoamine Dendrimer on Gene Transfer Efficiency of the Dendrimer Conjugate with α-Cyclodextrin.
    Kihara, Fumihiro; Arima, Hidetoshi; Tsutsumi, Toshihito; Hirayama, Fumitoshi; Uekama, Kaneto:
    Bioconjugate Chem., 13, 211-1219 (2002). abstract
  159. 6-O-α-(4-O-α-D-glucuronyl)-D-glucosyl-β-cyclodextrin: solubilizing ability and some cellular effects.
    Tavornvipas, Sumitra; Hirayama, Fumitoshi; Arima, Hidetoshi; Uekama, Kaneto; Ishiguro, Toshihiro; Oka, Masahide; Hamayasu, Kenichi; Hashimoto, Hitoshi:
    Int. J. Pharm., 249, 199-209 (2002). abstract
  160. Inclusion complex formation of captopril with α- and β-cyclodextrins in aqueous solution: NMR spectroscopic and molecular dynamic studies.
    Ikeda, Yoichi; Motoune, Sohko; Matsuoka, Toshikazu; Arima, Hidetoshi; Hirayama, Fumitoshi; Uekama, Kaneto:
    J. Pharm. Sci., 91, 2390-2398 (2002). abstract
  161. Cyclodextrin conjugate-based controlled release system: repeated- and prolonged-releases of ketoprofen after oral administration in rats
    Makoto Kamada, Fumitoshi Hirayama, Koichi Udo, Hideki Yano, Hidetoshi Arima and Kaneto Uekama:
    J. Control. Rel., 82, 407-416 (2002). abstract
  162. Colon-specific delivery of prednisolone-appended α-cyclodextrin conjugate: alleviation of systemic side effect after oral administration
    Hideki Yano, Fumitoshi Hirayama, Makoto Kamada, Hidetoshi Arima and Kaneto Uekama:
    J. Control. Rel., 79, 103-112 (2002). abstract
  163. Enhancement of Gene Expression by Polyamidoamine Dendrimer Conjugates with α-, β-, γ-Cyclodextrins.
    H. Arima, F. Kihara, F. Hirayama, and K. Uekama:
    Bioconjugate Chem., 12, 476-484 (2001). abstract
  164. A Moderate Interaction of Maltosyl-α-cyclodextrin with Caco-2 Cells in Comparison with the Parent Cyclodextrin.
    N. Ono, H. Arima, F. Hirayama, and K. Uekama:
    Biol. Pharm. Bull., 24,395-402 (2001). abstract
  165. Transparent, Adhesive Film Formation of Per-O-valeryl-β-cyclodextrin.
    F. Hirayama, K. Zaoh, K. Harata, W. Saenger and K. Uekama:
    Chem. Lett., 636-637 (2001). abstract
  166. Analysis of Phase Solubility Diagram of Phenacetin/Competitor/β-Cyclodextrin Ternary System, Involving Competitive Inclusion Complexation.
    N. Ono, F. Hirayama, H. Arima, and K. Uekama:
    Chem. Pharm. Bull., 49,78-81 (2001). abstract
  167. Improvement of some pharmaceutical properties of DY-9760e by sulfobutyl ether β-cyclodextrin
    Y. Nagase, M. Hirata, K. Wada b, H. Arima, F. Hirayama, T. Irie, M. Kikuchi, K. Uekama
    Int. J. Pharm., 229, 163-172 (2001). abstract
  168. Effect of Peracylation of β-Cyclodextrin on the Molecular Structure and on the Formation of Inclision Complexes: An X-Ray Study:
    M. Anibarro, K. Gessler, I. Uson, G. M. Sheldrick, K. Harata, K. Uekama, F. Hirayama, Y. Abe and W. Saenger:
    J. Am. Chem. Soc., 123, 11854-11862 (2001) abstract
  169. Contribution of P-glycoprotein to Enhancing Effects of Dimethyl-β-cyclodextrin on Oral Bioavailability of Tacrolimus.
    H. Arima, K. Yunomae, F. Hirayama, and K. Uekama:
    J. Pharmacol. Exp. Ther., 297, 547-555 (2001). abstract
  170. Preparation of Prednisolone-appended α-, β-, and γ-Cyclodextrins: Substitution at Secondary Hydroxyl Groups and In Vitro Hydrolysis Behavior.
    H. Yano, F. Hirayama, H. Arima and K. Uekama:
    J. Pharm. Sci., 90, 493-503 (2001). abstract
  171. Comparative Studies of the Enhancing Effects of Cyclodextrins on the Solubility and Oral Bioavailability of Tacrolimus in Rats.
    H. Arima, K. Yunomae, K. Miyake, T. Irie, F. Hirayama, and K. Uekama:
    J. Pharm. Sci., 90, 690-701 (2001). abstract
  172. Prednisolone-appended α-Cyclodextrin: Alleviation of Systemic Adverse Effect of Prednisolone after Intracolonic Administration in 2,4,6-Trinitrobenzenesulfonic Acid Induced Colitis Rats.
    H. Yano, F. Hirayama, H. Arima and K. Uekama:
    J. Pharm. Sci., 90, 2103-2112 (2001). abstract
  173. Inhibitory Effects of Novel Hydrophilic Cyclodextrin Derivatives on Nitric Oxide Production in Mcropharges Stimulated with Lipopolysaccharide.
    H. Arima, Y. Nishimoto, K. Motoyama, F. Hirayama and K. Uekama:
    Pharm. Res., 18(8), 1167-1173 (2001). abstract
  174. Stabilizing and Solubilizing Effects of Sulphobutyl Ether β-Cyclodextrin (SBE-β-CyD) on Prostaglandin E 1 Analogue.
    K. Uekama, Y. Hieda, F. Hirayama, H. Arima, M. Sudoh, A. Yagi, and H. Terashima:
    Pharm. Res., 18,1578-1585 (2001). abstract
  175. Crystal Structures of Heptakis(2,6-di-O-ethyl)cyclomaltoheptaose [Heptakis(2,6-di-O- ethyl)-β-cyclodextrin]. Solvent-regulated Helical Assembly of Macrocycles.
    K. Harata, F. Hirayama, and K. Uekama:
    Carbohydr. Res., 329, 597-607 (2000).
  176. Effects of Ageing on Crystallization, Dissolution and Absorption Characteristics of Amorphous Tolbutamide/2-Hydroxypropyl-β-cyclodextrin Complex.
    K. Kimura, F. Hirayama, H. Arima, and K. Uekama:
    Chem. Pharm. Bull., 48, 646-650 (2000).
  177. Hydrolysis Behavior of Prednisolone 21-Succinate/β-Cyclodextrin Amide Conjugate: Involvement of Intramolecular Catalysis of Amide Group in Drug Release.
    H. Yano, F. Hirayama, H. Arima and K. Uekama:
    Chem. Pharm. Bull., 48, 1125-1128 (2000).
  178. Inclusion Complex of 3,9-Bis(N,N-dimethylcarbamoyloxy)-5H-benzofuro[3,2-c] quinoline- 6-one (KCA-098) with Heptakis(2,6-di-O-methyl)-β-cyclodextrin: Interaction and Dissolution Properties.
    T. Yamada, T. Imai, K. Ohuchi, M. Otagiri, F. Hirayama, and K. Uekama:
    Chem. Pharm. Bull., 48, 1264-1269 (2000).
  179. X-ray Crystallographic Characterization of Nilvadipine Monohydrate and Its Phase Transition Behavior.
    F. Hirayama, M. Honjo, H. Arima, K. Okimoto, and K. Uekama:
    Eur. J. Pharm. Sci., 11, 81-88 (2000).
  180. Controlled Release of a Water-soluble Drug, Captopril, by a Combination of Hydrophilic and Hydrophobic Cyclodextrin Derivatives.
    Y. Ikeda, K. Kimura, F. Hirayama, H. Arima, and K. Uekama:
    J. Control. Rel., 66, 271-280 (2000).
  181. Improvement in Some Physicochemical and Biological Properties of LG106W by Inclusion Complexation with β-Cyclodextrin and Its Derivatives.
    S.H. Jeong, C.K. Lee, W.G. Cho, S.H. Kang, and K. Uekama:
    J. Cosmet. Sci., 51, 227-237 (2000).
  182. Improvements of Subcutaneous Bioavailability of Insulin by Sulfobutyl Ether β- Cyclodextrin in Rats.
    K. Tokihiro, H. Arima, S. Tajiri, T. Irie, F. Hirayama, and K. Uekama,
    J. Pharm. Pharmacol., 52, 911-917 (2000).
  183. Release Characteristics of a Short-chain Fatty Acid, n-Butylic Acid, from Its β-Cyclodextrin Ester Conjugates in Rat Biological Media.
    F. Hirayama, T. Ogata, H. Yano, H. Arima, K. Udo, M. Takano, K. Uekama:
    J. Pharm. Sci., 89, 1486-1495 (2000).
  184. Improvement of Solubility and Oral Bioavailability of Rutin by Complexation with 2-Hydroxypropyl-β-cyclodextrin.
    K. Miyake, H. Arima, F. Hirayama, M. Yamamoto, T. Horikawa, H. Sumiyoshi, S. Noda, and K. Uekama:
    Pharm. Devel. Tech., 5, 399-407 (2000).
  185. Enhanced Absorption of Cyclosporin A by Complexation with Dimethyl-β-cyclodextrin in Bile Duct-Cannulated and -Noncannulated Rats.
    K. Miyake, H. Arima, T. Irie, F. Hirayama, and K. Uekama:
    Biol. Pharm. Bull., 22, 66-72 (1999).
  186. Inhibitory Effect of 2-Hydroxypropyl-β-cyclodextrin on the Foaming Generated by the Phosphodiester Compound of Vitamin C and E, EPC-K1.
    Y. Hamano, K. Ito, H. Matsuda, H. Arima, H. Sumiyoshi, F. Hirayama, and K. Uekama:
    Chem. Pharm. Bull., 47, 828-832 (1999).
  187. Release-control of a Water-soluble Drug by Film-forming Trivaleryl-β-cyclodextrin.
    M. Yamada, F. Hirayama, and K. Uekama:
    Drug Delivery System, 14, 27-32 (1999).
  188. Determination of Stability Constant of β-Cyclodextrin Complexes by Membrane Permeation Technique and Permeation Behavior of Drug/Competing Agent/β-Cyclodextrin Ternary System.
    N. Ono, F. Hirayama, H. Arima, and K. Uekama:
    Eur. J. Pharm. Sci., 88, 133-139 (1999).
  189. Characterization of Itraconazole/2-Hydroxypropyl-β-cyclodextrin Inclusion Complex in Aqueous Propylene Glycol Solution.
    K. Miyake, T. Irie, H. Arima, F. Hirayama, K. Uekama, M. Hirano, and Y. Okamoto:
    Int. J. Pharm., 179, 237-245 (1999).
  190. Factors Affecting Membrane Controlled Drug Release for an Osmotic Pump Tablet (OPT) Utilizing (SBE)7m-β-Cyclodextrin as both a Solubilizer and Osmotic Agent.
    K. Okimoto, A. Ohike, R. Ibuki, N. Ohnishi, R.A. Rajewski, V.J. Stella, T. Irie, and K. Uekama:
    J. Control. Rel., 60, 311-319 (1999).
  191. Solubility and Mass and Nuclear Magnetic Resonance Spectroscopic Studies on Interaction of Cyclosporin A with Dimethyl-α- and β-Cyclodextrins in Aqueous Solution.
    K. Miyake, F. Hirayama, and K. Uekama:
    J. Pharm. Sci., 88, 39-45 (1999).
  192. Characterization of Tolbutamide Polymorphs (Burger's Forms II and IV) and Polymorphic Polymorphic Transition Behavior.
    K. Kimura, F. Hirayama, and K. Uekama:
    J. Pharm. Sci., 88, 385-391 (1999).
  193. Heptakis(2,6-di-O-methyl-3-O-acetyl)-β-cyclodextrin: A Water-soluble Cyclodextrin Derivative with Low Hemolytic Activity.
    F. Hirayama, S. Mieda, Y. Miyamoto, H. Arima, and K. Uekama:
    J. Pharm. Sci., 88, 970-975 (1999).
  194. Solid-state 13C Nuclear Magnetic Resonance Spectroscopic Study on Amorphous Solid Complexes of Tolbutamide with 2-Hydroxypropyl-α and β-Cyclodextrins.
    K. Kimura, F. Hirayama, H. Arima, and K. Uekama:
    Pharm. Res., 16, 1729-1734 (1999).
  195. Design and Evaluation of an Osmotic Pump Tablet (OPT) for Chlorpromazine Using (SBE)7m-β-cyclodextrin.
    K. Okimoto, A. Ohike, R. Ibuki, N. Ohnishi, R.A. Rajewski, V.J. Stella, T. Irie, and K. Uekama:
    Pharm. Res., 16, 549-554 (1999).
  196. Homogeneous Assay for Measuring Low-Density Lipoprotein Cholesterol in Serum with Triblock Copolymer and α-Cyclodextrin Sulfate.
    H. Sugiuchi, T. Irie, Y. Uji, T. Ueno, T. Chaen, K. Uekama, and H. Okabe:
    Clin. Chem., 44, 522-531 (1998).
  197. Improvements of Gastrointestinal Absorption and Lymphatic Transfer of Cyclosporin A by Various Cyclodextrins.
    K. Miyake, T. Irie, F. Hirayama, and K. Uekama:
    Drug Delivery System, 13, 369-375 (1998).
  198. Enhancing Effect of Hydroxypropyl-β-cyclodextrin on Cutaneous Penetration and Activation of Ethyl 4-Biphenylyl Acetate in Hairless Mouse Skin.
    H. Arima, T. Miyaji, T. Irie, F. Hirayama and K. Uekama:
    Eur. J. Pharm. Sci., 6, 53-59 (1998).
  199. Colon-specific Drug Delivery Based on a Cyclodextrin Prodrug: Release Behavior of Biphenylylacetic Acid from Its Cyclodextrin Conjugates in Rat Intestinal Tracts after Oral Administration.
    K. Minami, F. Hirayama, and K. Uekama:
    J. Pharm. Sci., 87, 715-720 (1998).
  200. Design and Evaluation of an Osmotic Pump Tablet (OPT) for Prednisolone, a Poorly Water-soluble Drug, Using (SBE)7m-β-Cyclodextrin.
    K. Okimoto, M. Miyake, N. Ohnishi, R.A. Rajewski, V.J. Stella, T. Irie, and K. Uekama:
    Pharm. Res., 15, 1562-1568 (1998).
  201. Spectroscopic Characterization of Inclusion Complex of a Luteinizing Hormone- Releasing Hormone Agonist, Buserelin Acetate, with Dimethyl-β-cyclodextrin.
    K. Matsubara, T. Irie and K. Uekama:
    Chem. Pharm. Bull., 45, 378-383 (1997).
  202. Varing Effects of Cyclodextrin Derivatives on Aggregation and Thermal Behavior of Insulin in Aqueous Solution.
    K. Tokihiro, T. Irie and K. Uekama:
    Chem. Pharm. Bull., 45, 525-531 (1997).
  203. Crystallization and Polymorphic Transition Behavior of Chloramphenicol Palmitate in 2-Hydroxypropyl-β-cyclodextrin Matrix.
    F. Hirayama, M. Usami, K. Kimura and K. Uekama:
    Eur. J. Pharm. Sci., 5, 23-30 (1997).
  204. Amorphous Spironolactone-Hydroxypropylated Cyclodextrins with Superior Dissolution and Oral Bioavailability.
    O.A. Soliman, K. Kimura, F. Hirayama, K. Uekama, H.M. El-Sabbagh, A.H. Abd El-Gawad and F.M. Hashim:
    Int. J. Pharm., 149, 73-83 (1997).
  205. Application of a β-Cyclodextrin Sulfate-immobilized Precolumn to Selective On-line Enrichment and Separation of Heparin-binding Proteins by Column-switching High performance Liquid Chromatography.
    K. Ishimaru, K. Fukunaga, T. Irie, K. Uekama, T. Ohta and H. Nakamura:
    J. Chromatogr. A, 769, 209-214 (1997).
  206. 6A-O-[(4-Biphenylyl)-acetyl]-α-, β- and γ-cyclodextrins and 6A-Deoxy-6A-amino [(4- biphenylyl)-acetyl]-α-, β-, and γ-cyclodextrins: Potential Prodrugs for Colon-Specific Delivery.
    K. Uekama, K. Minami, and F. Hirayama:
    J. Med. Chem., 40, 2755-2761 (1997).
  207. Protection Afforded by Maltosyl-β-cyclodextrin against α-Chymotrypsin-catalyzed Hydrolysis of a Luteinizing Hormone-releasing Hormone Agonist, Buserelin Acetate.
    K. Matsubara, Y. Ando, T. Irie, and K. Uekama:
    Pharm. Res., 14, 1401-1405 (1997).
  208. Combination Effects of α-Cyclodextrin and Xanthan Gum on Rectal Absorption and Metabolism of Morphine from Hollow-Type Suppositories in Rabbits.
    T. Kondo, T. Irie and K. Uekama:
    Biol. Pharm. Bull., 19, 280-286 (1996).
  209. Crystal Structures of Hexakis-(2,6-di-O-methyl)cyclomaltohexaose (Dimethyl-α-cyclodextrin) Crystallized from Acetone, and Crystallized from Hot Water.
    T. Steiner, F. Hirayama, and W. Saenger:
    Carbohydr. Res., 296, 69-82 (1996).
  210. 2-Hydroxypropylated Cyclodextrins as Sustained-release Carrier for Fragrance Materials.
    M. Tanaka, H. Matsuda,H. Sumiyoshi, H. Arima, F. Hirayama, K. Uekama, and S. Tsuchiya:
    Chem. Pharm. Bull., 44, 416-420 (1996).
  211. Possible Enhancing Mechanism of Cutaneous Permeation of 4-Biphenylylacetic Acid by β-Cyclodextrin Derivatives in Hydrophilic Ointment.
    H. Arima, T. Miyaji, T. Irie, F. Hirayama, and K. Uekama:
    Chem. Pharm. Bull., 44, 582-586 (1996).
  212. Effects of Cyclodextrin Derivatives on Systemic Absorption of Morphine through Nasal Cavity and Entry into Central Nervous System.
    T. Kondo, T. Irie and K. Uekama:
    Drug Delivery System, 11, 99-104 (1996).　
  213. Controlled Transdermal Delivery of Beraprost, a Prostaglandin I 2 Analogue, by Conbined Use of Fatty Acid and Cyclodextrins.
    Y. Ogata, H. Adachi, T. Irie and K. Uekama:
    Drug Delivery System, 11, 435-440 (1996).
  214. In-Vitro Evaluation of Biphenylylacetic Acid-β-Cyclodextrin Conjugates as Colon Targeting Prodrugs: Drug Release Behaviour in Rat Biological Media.
    F. Hirayama, K. Minami and K. Uekama:
    J. Pharm. Pharmacol., 48, 27-31 (1996).
  215. The Interaction of Charged and Uncharged Drugs with Neutral (HP-β-CD) and Anionically Charged (SBE7-β-CD) β-Cyclodextrins.
    K. Okimoto, R.A. Rajewski, K. Uekama, J.A. Jona and V. J. Stella:
    Pharm. Res., 13, 256-264 (1996).
  216. Mass Spectroscopic Evidence on Inhibiting Effect of Maltosyl-β-cyclodextrin on Insulin Self-Association.
    K. Tokihiro, T. Irie, F. Hirayama and K. Uekama:
    Pharm. Sci., 2, 519-522 (1996).
  217. Controlled Release of Diltiazem by a Combination of Short- and Long-Chain Peracylated-β-Cyclodextrins in Dogs.
    O.A. Soliman, K. Kimura, F. Hirayama, K. Uekama, H.M. El-Sabbagh, A.H. Abd El-Gawad and F.M. Hashim:
    Pharm. Sci., 2, 533-536 (1996).
  218. Characterization of Peracylated β-Cyclodextrins with Different Chain Lengths as a Novel Sustained Release Carrier for Water-soluble Drugs.
    F. Hirayama, M. Yamanaka, T. Horikawa and K. Uekama:
    Chem. Pharm. Bull., 43, 130-136 (1995).
  219. Improvement of Dissolution Characteristics of a New Chalcone Derivative, SU-740: Comparison between Size Reduction, Solid Dispersion and Inclusion Complexation.
    S. Ito, M. Demachi, Y. Toriumi, T. Adachi, S. Itai, F. Hirayama and K. Uekama:
    Chem. Pharm. Bull., 43, 2221-2225 (1995).
  220. Enhanced Nasal Delivery of LHRH Agonist Buserelin by Oleic Acid Solubilized and Stabilized in Hydroxypropyl-β-cyclodextrin.
    K. Abe, T. Irie and K. Uekama:
    Chem. Pharm. Bull., 43, 2232-2237 (1995).
  221. Preparation of β-Cyclodextrin Sulphate-immobilized Hydrophilic Vinyl-polymer Gel as a Selective, High Recovery and Stable Adsorbent for High-Performance Affinity Chromatography of Heparin-binding Substances.
    K. Ishimura, K. Fukunaga, T. Ohta, H. Nakamura, T. Irie and K. Uekama:
    Chromatographia, 41, 349-352 (1995).
  222. Direct Measurement of High-Density Lipoprotein Cholesterol in Serum with a Combination of Polyethylene Glycol-modified Enzymes and Sulfated α-Cyclodextrin.
    H. Sugiuchi, Y. Uji, H. Okabe, T. Irie, K. Uekama, N. Kayahara and K. Miyauchi:
    Clin. Chem., 41, 717-723 (1995).
  223. Cyclodextrin Sulfates in Parenteral Use: Protection against Gentamicin Nephrotoxicity in the Rat.
    K. Shiotani, T. Irie, K. Uekama and Y. Ishimaru:
    Eur. J. Pharm. Sci., 3, 139-151 (1995).
  224. Improvement of Dissolution Characteristics of 4-Butyl-2'-carboxy-methoxy -4'-(3-methyl- 2-butenyloxy)chalcone by β-Cyclodextrin Complexation.
    S. Ito, Y. Toriumi, M. Demachi, T. Adachi, Y. Ito, H. Hayashi, F. Hirayama and K. Uekama:
    Eur. J. Pharm. Sci., 3, 323-328 (1995).
  225. Combined Use of 2-Hydroxypropyl-β-cyclodextrin and Lipophilic　Absorption Enhancer in Nasal delivery of LHRH Agonist, Buserelin Acetate in Rats.
    K. Abe, T. Irie, H. Adachi and K. Uekama:
    Int. J. Pharm., 123, 103-112 (1995).
  226. In-vivo and In-vitro Correlation for Delayed-release Behaviour of a Molsidomine/ O-Carboxymethyl-O-ethyl-β-cyclodextrin Complex in Gastric Acidity-controlled Dogs.
    T. Horikawa, F. Hirayama and K. Uekama
    J. Pharm. Pharmacol., 47, 124-127 (1995).
  227. Modification of Rectal Absorption of Morphine from Hollow-type Suppositories with a Combination of α-Cyclodextrin and Viscosity-enhancing Polysaccharide.
    K. Uekama, T. Kondo, K. Nakamura, T. Irie, K. Arakawa, M. Shibuya and J. Tanaka:
    J. Pharm. Sci., 84, 15-20 (1995).
  228. Improvement of Nasal Bioavailability of an LHRH Agonist Buserelin by Cyclodextrin Derivatives in Rats.
    K. Matsubara, K. Abe, T. Irie and K. Uekama:
    J. Pharm. Sci., 84, 1295-1300 (1995).
  229. Differential Effects of Sulfate and Sulfobutyl Ether of β-Cyclodextrin on Erythrocyte Membranes in Vitro.
    K. Shiotani, K. Uehata, T. Irie, K. Uekama, D.O. Thompson and V.J. Stella:
    Pharm. Res., 12, 77-83 (1995).
  230. Potential Use of Maltosyl-β-cyclodextrin for Inhibition of Insulin Self-association in Aqueous Solution.
    K. Tokihiro, T. Irie, K. Uekama and J. Pitha:
    Pharm. Sci., 1, 49-53 (1995).
  231. Cyclodextrin Derivatives that Modify Nasal Absorption of Morphine and Its Entry into Cerebrospinal Fluid in the Rat.
    T. Kondo, K. Nishimura, T. Irie and K. Uekama:
    Pharm. Sci., 1, 163-166 (1995).
  232. Enhanced Bioavailability and Reduced Metabolism of Salbutamol by Perbutanoyl β-cyclodextrin after Oral Administration in Dogs.
    F. Hirayama, T. Horikawa, M. Yamanaka and K. Uekama:
    Pharm. Sci., 1, 517-520 (1995).
  233. Optimal Use of Absorption Enhancer HPE-101 Solubilized in Hydroxypropyl-β-cyclodextrin for Facilitating Nasal Permeability in Rats.
    K. Abe, T. Irie and K. Uekama:
    Pharm. Sci., 1, 563-567 (1995).
  234. Percutaneous Penetration and Metabolism of Salicylic Acid Derivatives Across Hairless Mouse Skin in Diffusion Cell In Vitro.
    N. Higo, S. Sato, T. Irie and K. Uekama:
    S.T.P. Pharma Sci., 5, 302-308 (1995).